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Abstract
Background: Recent genome-wide studies identified a risk locus for colorectal cancer at 18q21, which maps to the SMAD7
gene. Our objective was to confirm the association between SMAD7 SNPs and colorectal cancer risk in the multi-center
Colon Cancer Family Registry.
Materials and Methods: 23 tagging SNPs in the SMAD7 gene were genotyped among 1,592 population-based and 253
clinic-based families. The SNP-colorectal cancer associations were assessed in multivariable conditional logistic regression.
Results: Among the population-based families, both SNPs rs12953717 (odds ratio, 1.29; 95% confidence interval, 1.12–1.49),
and rs11874392 (odds ratio, 0.80; 95% confidence interval, 0.70–0.92) were associated with risk of colorectal cancer. These
associations were similar among the population- and the clinic-based families, though they were significant only among the
former. Marginally significant differences in the SNP-colorectal cancer associations were observed by use of nonsteroidal
anti-inflammatory drugs, cigarette smoking, body mass index, and history of polyps.
Conclusions: SMAD7 SNPs were associated with colorectal cancer risk in the Colon Cancer Family Registry. There was
evidence suggesting that the association between rs12953717 and colorectal cancer risk may be modified by factors such as
smoking and use of nonsteroidal anti-inflammatory drugs.
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Introduction
It is estimated that inherited susceptibility contributes to ,35%
of all colorectal cancer (CRC) cases [1]. Recent progress through
the application of genome-wide association studies (GWASs) have
identified a number of common variants involved in the etiology of
CRC[2]. Two GWAS [3,4] identified a risk locus for CRC at
18q21, which maps to SMAD7, a functional candidate gene for
CRC. Smad7 plays inhibitory roles in the transforming growth
factor beta (TGF-b) signaling pathway [5,6] which is involved in
many cellular processes and has an important role in cancer
development and progression [7]. Broderick et al. [3] identified
three SNPs (rs4939827, rs12953717, rs4464148) in SMAD7
associated with CRC and the SNP rs4939827 was later replicated
as the top-ranking SNP at 18q21 by Tenesa et al. [4]. The
association between rs4939827 and CRC risk was also confirmed
in a recent meta-analysis [8]; however, significant between-study
heterogeneity was observed. In addition, these susceptibility
variants were found to be enriched in familial CRC [9,10].
Furthermore, SMAD7 expression was found to be lower in
colorectal cancers than in adenomas regardless of 18q copy
number status [11] and the risk allele at rs12953717 was
significantly associated with lower SMAD7 expression in lympho-
blastoid cell lines [3], suggesting that allele-specific expression of
SMAD7 is likely to be the biological mechanism underlying the
association between variations in 18q21 and CRC risk.
Given the SMAD7’s role in the TGF-b signaling pathway [12]
and the significant between-study heterogeneity in the reported
association between SMAD7 SNPs and CRC risk, we looked to
confirm the association between SMAD7 SNPs and CRC risk in a
large family-based case-control study based on the multi-center
Colon Cancer Family Registry (Colon CFR), and to examine gene
X environmental interactions to identify risk/protective factors
that may affect the association between SMAD7 SNPs and CRC
risk. Our case-unaffected sibling study design has been shown to
be more powerful for controlling potential confounding from




Data for this study were obtained through the Colon CFR, a
National Cancer Institute (NCI)–funded registry of CRC cases,
unaffected family members, and population-based controls. The
registry is described in detail in Newcomb et al. [14] and Levine et
al. [15]. Briefly, the Colon CFR is an international collaborative
study initiated in 1997. Participants were recruited from six centers
including centers in the University of Southern California
Consortium (Arizona, Cleveland Clinic, Colorado, Dartmouth,
Minnesota, North Carolina, and University of Southern Califor-
nia), Hawaii (Honolulu), Fred Hutchinson Cancer Research
Center (Seattle, WA), Mayo Clinic (Rochester, MN), Cancer
Care Ontario (Toronto, Canada), and University of Melbourne
(Victoria, Australia) using population-based and clinic-based
ascertainment strategies. Cases were recruited in two phases, from
1998 to 2002 (phase 1) and from 2002 to 2007 (phase 2). Phase 2
subjects were enriched in cases more likely to have a family history
of CRC. All centers except Fred Hutchinson Cancer Research
Center oversampled cases with multiple first-degree relatives
reporting CRC or CRC cases diagnosed under age 50 to target
families with excess CRC risk. First-degree and some second-
degree relatives with CRC were also recruited from families with
multiple CRC cases. The clinic-based sample represents multiple-
case families at high risk of Hereditary Non-Polyposis Colorectal
Cancer or other familial CRC phenotypes.
In the Colon CFR, population-based controls were only
obtained from one of the Colon CFR sites (Fred Hutchinson
Cancer Research Center), and the total sample size (N = 429) is
much smaller than that of the sibling controls (N = 3,115). To
make the most use of the available genetic data, in this
investigation we used a case/unaffected sibling control design[13]
with data from both population-based and clinic-based families in
the main effect analyses. Cases were probands and siblings
diagnosed with CRC and controls were siblings without CRC at
the time of ascertainment. Diagnosis of CRC was based on the
following six categories of confirmation [14]: pathologist review of
slides; review of pathology report; cancer registry report or
medical record(s) indicating treatment for the specific type of
cancer; report on a death certificate; self-report; and report by a
relative. Therefore, the unaffected status of the siblings was not
established through colonoscopy. All cases were interviewed within
5 years of diagnosis (76% within 2 years). There were too few
clinic-based case/control pairs for stratified analyses so all
stratified analyses used the population-based families only. We
excluded monozygous twins and subjects with unknown age or
gender, and included only non-Hispanic white subjects. In
addition, we also genotyped a random set of unrelated popula-
tion-based controls (n = 429) from one of the Colon CFR sites
(Fred Hutchinson Cancer Research Center). A total of 1,923 cases
(1,640 population-based and 283 clinic-based) and their 3,115
unaffected sibling controls (2,621 population-based and 494 clinic-
based) were included in the analyses.
Ethics
All subjects signed an informed consent before providing data to
the Colon CFR. Ethics approval for the study was obtained from
the Institutional Review Boards at each CCFR site: University of
Southern California Health Sciences Institutional Review Board,
Mount Sinai Hospital Ethics Research Board, University of
Hawaii Institutional Review Board, The University of Melbourne
Central Human Research Ethics Committee, Fred Hutchinson
Cancer Research Center Institutional Review Board, and Mayo
Clinic Institutional Review Board.
SNP Selection and genotyping
SMAD7 was genotyped as part of an ongoing study of genes
relevant to lipid peroxidation and apoptosis (5R01CA114472-02).
Tagging single nucleotide polymorphisms (SNPs) were selected
using the program Snagger20 [16] to cover all SNPs with a minor
allele frequency (MAF) of $0.05 or greater with a pairwise r2 of
$0.80 in the region covering each gene of interest as well as 20 kb
upstream and 10 kb downstream of the gene. The linkage
disequilibrium blocks were determined using data from the
International HapMap Project White CEPH (Utah residents with
ancestry from northern and western Europe) population (Hap-
Map, release 21, July 2006; www.hapmap.org). Finally, three
GWAS-identified SNPs, rs4939827, rs12953717, rs4464148, were
also included. SNPs were genotyped on the Illumina GoldenGate
platform (Illumina, Inc., San Diego, CA) [17] in the University of
Southern California, Norris Comprehensive Cancer Center,
Molecular Genomics Core facility, using DNA extracted from
blood samples [14]. Quality control measures included testing for
deviations from Hardy-Weinberg equilibrium (HWE) in non-
Hispanic Whites, the inclusion of blinded interplate and intraplate
replicates, and mixing cases and controls on genotyping plates.
SNPs were excluded from the analysis if there were more than two
errors on the replicate genotypes. Marker rs4939827 failed on the
SMAD7 and Colorectal Cancer Risk
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60464
Illumina platform and was subsequently excluded. In this analysis,
we report results for 23 tSNPs in SMAD7. A total of 133 blinded
duplicate pairs were included for genotyping. Concordance for the
duplicate samples was .99%.
Microsatellite Instability Testing
All available tumors from the Colon CFR’s Jeremy Jass
Memorial Pathology Bank were assayed for instability at the
following 10 microsatellites: BAT25, BAT26, BAT40, BAT34C4,
D5S346, D17S250, D18S55, D10S197, ACTC, and MYCL as
described previously [14]. Only subjects with clear results for at
least four markers were included. Microsatellite Instability (MSI)
data were available for 1,242 (64.4%) of cases (1,106 population-
based and 136 clinic-based). Instability at .30% of the tested loci
was defined as microsatellite instability high (MSI-H); instability at
.10% of loci but ,30% of loci was defined as microsatellite
instability low (MSI-L); and those with instability at 0 loci were
categorized as microsatellite stable (MSS).
Tumor Location
Tumor location was obtained from the pathology report and
was available for 1,778 (92.1%) of cases (1,566 population-based
and 212 clinic-based). Right colon was defined as the cecum
through the splenic flexure; left colon included the descending
colon through the sigmoid colon; rectal tumors included the
rectosigmoid junction and the rectum.
Statistical Analysis
All statistical analyses were conducted using the R programming
language and SAS v9.1 (SAS Institute Inc., Cary, NC).
MAF was estimated from the genotype data from unrelated
population-based controls. Pairwise linkage disequilibrium be-
tween SNPs was estimated using the square of the correlation
coefficient (R2) and D-prime (D9) between markers. We also
evaluated Hardy-Weinberg equilibrium for each SNP. No
deviations were observed for all SNPs except rs1873190. Among
the unrelated population-based controls, statistically significant
reduced numbers of heterozygous genotypes of rs1873190 (155
observed vs. 186 expected under HWE; P exact = 0.0006) were
observed. The genotyping data of this SNP showed clear genotype
separation with a call rate of 98% and concordance rates of 100%
among replicates.
In the analysis of main effects, the population- and clinic-based
data were analyzed separately. We used multivariable conditional
logistic regression with sibship as the matching factor and
controlled for age (continuous) and sex. We assessed the SNP-
CRC associations assuming a log-additive model. In all analyses,
the lower frequency allele was coded as the ‘‘risk’’ allele and
individuals were assigned a 0, 1, or 2 representing the number of
risk alleles they possessed for that SNP. Test for haplotypic
association was performed using SAS/Genetics and haplotype
frequencies were estimated by the expectation–maximization
algorithm.
Among the population-based families, we also examined the
possibility that the SNP-CRC association was modified by other
factors including gender, age, use of nonsteroidal anti-inflamma-
tory drugs (NSAIDs), cigarette smoking, alcohol drinking, body
mass index (BMI), physical activity (average weekly metabolic
equivalent (MET) hours of physical activity throughout adult-
hood), history of diabetes, polyps, and ulcerative colitis, and family
history of CRC in a first-degree relative as reported by the
proband. All analyses within the exposure strata were specified in
advance based on indications for potential effect modification in
the literature. To test this hypothesis, dummy variables represent-
ing stratum-specific exposure were created for estimating stratum-
specific results in one single conditional logistic regression model.
P-values for interactions were estimated from likelihood ratio tests.
We also evaluated differences in the association by tumor location
(right, left, rectum/rectosigmoid junction) and MSI status (MSS,
MSI-L and MSI-H) by stratifying the matched sets on the tumor
characteristics of the case. We assigned the sets the MSI or tumor-
site category of the case and included interaction terms in the
conditional logistic regression models to estimate these stratum-
specific odds ratios. Finally, we considered whether inclusion of
cases recruited .2 years after diagnosis resulted in biased
estimates and results were fundamentally unchanged after
exclusion of these cases (data not shown).
Results
Table 1 shows the demographic characteristics of the study
population. A total of 1,854 sibships were included in this study.
Among the participants, 1,640 cases and 2,621 controls were
population-based and 283 cases and 494 controls were clinic-
based. Data for tumor site and MSI status were available for 1,778
cases and 1,242 cases respectively.
Results of the single SNP analysis are shown in Table 2. SNPs
were sorted according to their position on chromosome 18.
Assuming a log-additive model, a total of seven SNPs had a P
value less than 0.05; after Bonferroni correction for the number of
SNPs tested in the SMAD7 gene, only two SNPs, rs11874392 and
rs12953717, remained significantly associated with CRC risk
among the population-based families. Each minor allele (T) of
rs12953717 SNP was associated with a significantly increased risk
of CRC (odds ratio-OR, 1.29; 95% confidence interval-CI, 1.12–
1.49), whereas each minor allele (T) of rs11874392 was associated
with a statistically significantly reduced risk of CRC (OR, 0.80;
95% CI, 0.70–0.92). These associations were similar among the
population-based families and the clinic-based families, though
they were only significant among the population-based families
with its larger sample size. The two SNPs were highly correlated
with each other (D9, 0.999; R2, 0.661). In a logistic regression
analysis, the inclusion of rs11874392 did not significantly improve
the fit of the model over that with rs12953717 alone (P = 0.88).
Analysis of rs12953717 and rs11874392 revealed that CT and TA
were the most common haplotypes (Table 3) and only TA was
associated with higher risk of CRC (P = 9.061025). Haplotype CA
was not associated with CRC risk (P = 0.53). No significant
associations were observed for the rs4464148 SNP or other SNPs
evaluated in SMAD7 after adjustment for multiple testing.
Among the population-based families, we assessed the associ-
ation between rs12953717 and CRC risk after stratification by
related risk/protective factors (Table 4). We observed modest and
marginally significant differences in the disease association by use
of NSAIDs, cigarette smoking, BMI and history of polyps. The
strongest associations were observed among current NSAID users,
non-/former smokers, overweight individuals (25#BMI,30) and
individuals with a prior diagnosis of polyps, respectively. There
were no statistically significant differences in the SNP-CRC
association according to gender, age, alcohol drinking, physical
activity, diabetes, and ulcerative colitis. The effect of rs12953717
seemed to be stronger among individuals without a family history
of CRC than among those with a family history; however, this
difference was not statistically significant (P = 0.39). When the
association between rs11874392 and risk of CRC was examined,
similar but less pronounced differences by the above factors were
observed.
SMAD7 and Colorectal Cancer Risk
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We also examined the possible heterogeneity of the SNP effect
by tumor location and MSI status (Table 5). The strongest
associations were observed for distal colon cancer and MSI-L/
MSI-H tumors than for other tumors; however, neither difference
was statistically significant.
To address potential survival bias due to the inclusion of cases
interviewed up to 5 years after diagnosis, we repeated the analyses
of main effects including only probands interviewed within 2 years
of diagnosis and their unaffected siblings and results were
fundamentally unchanged (data not shown).
Table 1. Selected characteristics of cases and sibling controls from participants in the Colon Cancer Family Registry.




(N = 2,621)1 P
4
Cases
(N = 283)1 Sibling controls (N = 494)1 P
4
Personal characteristics
Mean age 6SD 53.6610.8 54.0611.7 ,0.001 49.6611.4 51.6611.9 ,0.001
Sex, no. (%)
Male 838 (51.1) 1,167 (44.5) ,0.001 143 (50.5) 210 (42.5) 0.039
Female 802 (48.9) 1,454 (55.5) 141 (49.5) 284 (57.5)
Center, no. (%)
Ontario, Canada 298 (18.2) 494 (18.9) - 0 (0) 0 (0) -
USC Consortium, U.S. 336 (20.5) 461 (17.6) 42 (14.8) 50 (10.1)
Melbourne, Australia 325 (19.8) 587 (22.4) 123 (43.5) 234 (47.4)
Hawaii, U.S. 7 (0.4) 8 (0.3) 0 (0) 0 (0)
Mayo Foundation, U.S. 271 (16.5) 516 (19.7) 118 (41.7) 210 (42.5)
Seattle, U.S. 403 (24.6) 555 (21.2) 0 (0) 0 (0)
BMI (kg/m2)2
15–18 (underweight) 17 (1.0) 23 (0.9) 0.049 6 (2.1) 13 (2.6) 0.53
18–25 (normal) 572 (34.9) 1,042 (39.8) 99 (35.0) 181 (36.6)
25–30 (overweight) 618 (37.7) 953 (36.4) 104 (36.8) 181 (36.6)
30+ (obese) 375 (22.9) 539 (20.6) 61 (21.6) 97 (19.6)
Unknown/missing 58 (3.5) 64 (2.4) 13 (4.6) 22 (4.5)
Physical activity (MET hours)3
0–6 (inactive) 391 (23.8) 604 (23.0) 0.005 42 (14.8) 100 (20.2) 0.63
6.1–20 (less active) 438 (26.7) 712(27.2) 55 (19.4) 119 (24.1)
20.1–44 (active) 392 (23.9) 590 (22.5) 72 (25.4) 129 (26.1)
44+ (very active) 345 (21.0) 565 (21.6) 112 (39.6) 141 (28.5)
Unknown/missing 74 (4.5) 150 (5.7) 2 (0.7) 5 (1.0)
Family history of CRC
No first-degree relative 1,093 (66.7) - 101 (35.7) -
$1 first-degree relative 475 (29.0) - 67 (23.7) -
Unknown/missing 72 (4.4) - 115 (40.6) -
Tumor characteristics
Site, no. (%)
Right colon 546 (33.3) - 87 (30.7) -
Left colon 477 (29.1) - 44 (15.6) -
Rectum 543 (33.1) - 81 (28.6) -
Unknown/missing 74 (4.5) - 71 (25.1) -
MSI, no. (%)
MSS 790 (48.2) - 62 (21.9) -
MSI-L 141 (8.6) - 15 (5.3) -
MSI-H 175 (10.7) - 59 (20.9) -
Unknown/missing 534 (32.6) - 147 (51.9) -
1Non-Hispanic white family-based discordant siblings with age and sex data. 2Self-reported weight and height 2 years prior to questionnaire completion date used to
calculate body mass index (BMI). 3Average weekly total lifetime MET hours. 4Estimated from 1-df likelihood ratio test from a conditional logistic regression model.
doi:10.1371/journal.pone.0060464.t001
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Discussion
Consistent with the two GWAS [3,4], we found a statistically
significant association between two SMAD7 polymorphisms,
rs12953717 and rs11874392, and CRC in this large family-based
case-control study. We observed suggestions that the association of
rs12953717 and CRC risk may be modified by use of NSAIDs,
cigarette smoking, BMI and history of polyps.
The underlying causal variant for the association between
18q21 variation and CRC risk remains unknown. Pittman et al.
[11] reported that a C to G SNP at 44,703,563 bp, a SNP in
strong linkage disequilibrium with other genetic variations around
18q21, may be the functional variant responsible for 18q21-
associated variations in CRC risk through differential SMAD7
expression and subsequent TGF-b signaling. Compared to the C
allele, the risk allele G forms weaker protein–DNA complexes with
nuclear extracts and was associated with a reduced expression of
SMAD7 in the colorectum. However, it remains unclear how such
alterations may promote carcinogenesis. It has been suggested that
SMAD7 may induce tumorigenicity by blocking TGF-b-induced
growth inhibition and apoptosis [18]. The expression of SMAD7 is
very low in epithelial tissues, but is up-regulated in several cancers.
Over-expression of SMAD7 has been shown to inhibit TGF-b-
mediated induction of endogenous heme oxygenase-1 (HO-1) gene
expression [19], an adaptive defense against oxidant stress [20]. In
colon cancer cells, stable expression of SMAD7 blocks the TGF-b-
mediated activation of NFkB[5], a critical molecule in oxidative-
stress-induced apoptosis. In addition, CRC patients with deletion
Table 2. SMAD7 tagging SNPs and colorectal cancer risk in the Colon Cancer Family Registry.
Location in Major/minor Population-based families Clinic-based families
Variant SMAD7 allele MAF1 Coordination OR (95% CI)2 P2 OR (95% CI)2 P2
rs9945724 39 UTR C/T 0.06 44694487 0.89 (0.67–1.18) 0.41 0.70 (0.36–1.35) 0.29
rs17186485 intron G/A 0.07 44703030 0.85 (0.66–1.10) 0.22 0.92 (0.49–1.70) 0.78
rs11874392 intron A/T 0.49 44707154 0.80 (0.70–0.92) 0.0016 0.83 (0.60–1.14) 0.24
rs4939826 intron C/A 0.08 44707404 0.91 (0.74–1.13) 0.38 0.91 (0.54–1.53) 0.72
rs12953717 intron C/T 0.43 44707927 1.29 (1.12–1.49) 0.0005 1.31 (0.91–1.89) 0.14
rs884013 intron C/T 0.05 44710128 0.97 (0.73–1.28) 0.81 1.01 (0.47–2.17) 0.98
rs12456328 intron C/T 0.14 44711094 1.15 (0.95–1.40) 0.15 0.64 (0.41–1.01) 0.054
rs6507876 intron T/G 0.09 44712919 0.94 (0.76–1.17) 0.57 0.98 (0.57–1.68) 0.93
rs4464148 intron T/C 0.31 44713030 1.16 (1.00–1.34) 0.049 1.10 (0.76–1.60) 0.61
rs2337107 intron C/T 0.40 44713321 1.13 (0.97–1.30) 0.11 1.20 (0.84–1.71) 0.31
rs7351039 intron G/A 0.07 44714654 0.84 (0.63–1.14) 0.26 1.02 (0.53–1.94) 0.96
rs2337106 intron G/C 0.47 44714901 0.94 (0.82–1.08) 0.39 1.05 (0.75–1.47) 0.77
rs7238442 intron T/C 0.46 44715784 1.07 (0.93–1.22) 0.34 1.08 (0.78–1.48) 0.65
rs4939830 intron G/A 0.09 44717056 1.16 (0.92–1.46) 0.20 0.73 (0.44–1.19) 0.20
rs4939832 intron A/G 0.23 44719663 0.84 (0.71–0.99) 0.037 0.88 (0.59–1.30) 0.51
rs1873190 intron G/A 0.33 44722354 0.90 (0.78–1.05) 0.17 1.17 (0.82–1.67) 0.38
rs3764482 intron G/A 0.21 44722944 0.94 (0.79–1.11) 0.47 1.32 (0.87–1.99) 0.19
rs1316447 intron G/A 0.18 44726674 1.20 (1.02–1.42) 0.028 0.89 (0.58–1.36) 0.59
rs3736242 intron C/T 0.22 44728744 0.97 (0.83–1.14) 0.73 1.09 (0.74–1.63) 0.66
rs4939837 59 UTR G/A 0.35 44741996 0.86 (0.74–1.00) 0.044 0.92 (0.63–1.35) 0.68
rs7240215 59 UTR C/T 0.22 44744179 1.18 (1.01–1.39) 0.037 0.96 (0.63–1.46) 0.84
rs1867100 59 UTR C/G 0.14 44747964 1.09 (0.90–1.33) 0.37 1.17 (0.77–1.79) 0.46
rs7237225 59 UTR T/A 0.16 44752394 1.07 (0.87–1.32) 0.50 1.01 (0.61–1.67) 0.97
1Minor allele frequencies (MAFs) were estimated using unrelated population-based controls. 2Results were estimated using a log-additive model, adjusted for age and
sex.
doi:10.1371/journal.pone.0060464.t002
Table 3. Colorectal cancer risk associated with haplotypes formed by SMAD7 SNPs rs12953717 and rs11874392.
Haplotype Frequency in cases Frequency in controls OR (95% CI)2 P2
CT 0.426 0.445 1.00
TA 0.469 0.442 1.67 (1.29–2.16) 9.061025
CA 0.098 0.102 1.14 (0.76–1.73) 0.53
TT 0.00003 0.0002 - -
doi:10.1371/journal.pone.0060464.t003
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of SMAD7 were found to have a favorable clinical outcome [21].
Conversely, amplification of this gene was associated with a
significantly worse prognosis, with a graded effect depending on
SMAD7 gene copy number [21].
Given that SMAD7 is involved in intestinal inflammation
through its regulation of TGF-b signaling [22,23] the association
between SMAD7 SNPs and CRC risk may be modified by factors
affecting inflammation. In human inflammatory bowel tissues,
TGF-b1 signaling is disrupted by the up-regulation of SMAD7,
leading to an enhanced production of inflammatory cytokines.
Inhibition of SMAD7 with a specific antisense oligonucleotide can
restore the immunosuppressive TGF-b1 signaling and suppress the
inflammatory cytokine production [23]. In our study, there is some
indication of differences in the association between rs12953717
and CRC risk by NSAID use, with the effect of the SNP being
most pronounced among current users and least among former
users. In a population-based case-control study of colon cancer,
Slattery et al. [24] also observed slightly stronger associations of
rs4939827 and rs12953717 for individuals reporting recent
aspirin/NSAID use. Our findings are also consistent with those
Table 4. Stratified analyses of rs12953717 and rs11874392 by known risk/protective factors among population-based families.
Risk associated with T allele of rs12953717 Risk associated with T allele of rs11874392
OR (95% CI)1 PWalds
1 PInteraction




Men 1.28 (1.07–1.54) 0.0073 0.91 0.82 (0.69–0.98) 0.026 0.66
Women 1.30 (1.09–1.55) 0.0034 0.79 (0.67–0.93) 0.0041
Age
,55 1.22 (1.01–1.46) 0.039 0.33 0.83 (0.70–0.98) 0.031 0.66
$55 1.38 (1.13–1.69) 0.0019 0.78 (0.65–0.95) 0.014
NSAIDs
Nonusers 1.30 (1.09–1.55) 0.0029 0.073 0.77 (0.66–0.91) 0.0017 0.34
Former users 1.06 (0.83–1.35) 0.63 0.92 (0.73–1.15) 0.47
Current users 1.53 (1.19–1.98) 0.0011 0.77 (0.60–0.97) 0.027
Cigarette smoking
Nonsmokers 1.37 (1.13–1.66) 0.0014 0.050 0.78 (0.65–0.93) 0.0066 0.26
Former smokers 1.36 (1.12–1.65) 0.0019 0.77 (0.64–0.92) 0.0043
Current smokers 0.89 (0.64–1.24) 0.50 1.00 (0.74–1.36) 0.98
Alcohol drinking
Nondrinkers 1.35 (1.06–1.73) 0.014 0.78 0.79 (0.63–0.98) 0.033 0.76
Former drinkers 1.33 (0.99–1.79) 0.057 0.74 (0.57–0.96) 0.021
Current drinkers 1.24 (1.04–1.48) 0.016 0.82 (0.69–0.96) 0.016
BMI
,25 1.19 (0.97–1.46) 0.098 0.053 0.82 (0.68–0.99) 0.043 0.39
25-,30 1.51 (1.23–1.86) 0.00008 0.74 (0.61–0.89) 0.0017
$30 1.09 (0.83–1.42) 0.53 0.89 (0.70–1.13) 0.33
Physical activity
Inactive or less active 1.23 (1.02–1.48) 0.030 0.73 0.77 (0.65–0.92) 0.0036 0.30
Active or very active 1.28 (1.06–1.55) 0.011 0.86 (0.72–1.02) 0.090
Diabetes
No 1.27 (1.09–1.47) 0.0017 0.52 0.80 (0.70–0.92) 0.0020 0.95
Yes 1.45 (0.97–2.15) 0.068 0.81 (0.56–1.17) 0.26
Polyps
No 1.13 (0.95–1.36) 0.18 0.087 0.89 (0.75–1.05) 0.16 0.22
Yes 1.39 (1.13–1.72) 0.0020 0.77 (0.64–0.94) 0.0098
Ulcerative Colitis
No 1.26 (1.08–1.46) 0.0025 0.68 0.81 (0.70–0.93) 0.0025 0.83
Yes 1.48 (0.68–3.23) 0.32 0.87 (0.44–1.72) 0.69
Family history of CRC
No first-degree relative 1.35 (1.13–1.61) 0.00077 0.39 0.75 (0.64–0.89) 0.00075 0.21
$1 first-degree relative 1.18 (0.90–1.56) 0.23 0.91 (0.71–1.16) 0.45
1Adjusted for age and sex. 2P for interaction was estimated from likelihood-ratio test.
doi:10.1371/journal.pone.0060464.t004
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from a recent study suggesting that CRC-specific survival in
postmenopausal women varied according to SMAD7 genotype
(rs4939827 and rs4464148) among patients who were regularly
using NSAIDs before diagnosis, but not among never-users and
former users of NSAIDs [25]. Studies have shown that disruption
of TGF-b1 signaling due to high levels of SMAD7 is a feature of
colitis and blocking SMAD7 restores TGF- b1 signaling in colitis
[26]. Since non-/former smokers have higher risk of ulcerative
colitis compared with current smokers [27], our observation of a
stronger SMAD7 SNP association among non-/former smokers
would lend some support to the inflammation hypothesis. We
consistently observed a higher CRC OR for rs12953717 among
individuals with ulcerative colitis than those without, although this
difference did not reach statistical significance, possibly due to the
small number of individuals with ulcerative colitis. On the other
hand, smoking increases the risk of the other form of IBD, Crohn’s
disease, but we were unable to examine the SNP-CRC association
stratified by history of Crohn’s disease due to the small number of
individuals with this disease (N = 32). In addition, the observation
of a BMI interaction could also suggest the involvement of
inflammation pathways, since obesity is associated with a state of
chronic inflammation [28]. However, the observation of the effect
of SMAD7 genetic variants only among overweight individuals but
not among obese individuals was unexpected and requires
confirmation.
SMAD7 may also function through insulin-related pathways.
SMAD7 protein expression in the renal cortex is decreased in
diabetes [29] and conditional expression of SMAD7 in pancreatic b
cells disrupts TGF-b signaling and induces reversible diabetes
mellitus [30]. In addition, the SMAD7 SNP rs3764482 (IVS2 –
21C.T) has been associated with a reduced risk of type 2 diabetes
in mice [31]. We explored this possible mechanism by examining
differences in the association of the SNP with CRC risk by
diabetes status but did not find strong evidence for an interaction
with diabetes (Table 3). The association between rs12953717 and
CRC risk remained among non-diabetic individuals.
In addition to confirming the associations between SMAD7
SNPs and CRC risk, we further defined these associations
according to other known risk/protective factors for CRC and
tumor characteristics. We found a stronger SNP association
among individuals with a prior history of polyps. Further
exploration by the type, number and size of polyps was not
performed because detailed information on these characteristics is
lacking. The exact biological mechanism for the interaction
between polyps and SMAD7 is unknown; however, a recent study
in prostate cancer cells found that SMAD7 can interact with
adenomatous polyposis coli (APC) protein in linking the TGF-b
type I receptors to the microtubule system to promote cell
migration [32], indicating a possible role of SMAD7 in the
progression from adenomatous polyps to CRCs. Interpretation of
this result needs to be cautious, because the proportion of subjects
who had been examined for polyps prior to cancer diagnosis is
unknown. There was some indication of differences in the effect of
SMAD7 SNPs by tumor location. We observed a significant
association of rs12953717 for distal colon tumors, but not for
proximal colon tumors and rectal tumors. Such finding is
consistent with Curtin et al. [33], who also reported significant
associations for distal colon tumors for two SMAD7 SNPs but not
for proximal colon and rectal tumors. Similarly, Slattery et al. [24]
observed slightly stronger associations for distal than for proximal
colon cancers. However, no significant difference in the effect size
of rs4939827 by tumor site was reported by Broderick et al. [3].
On the contrary, Tenesa et al. [4] found that rs4939827 was more
strongly associated with risk of rectal cancer than for colon cancer.
Consistent with most prior studies [4,24,34], we did not find any
significant differences in the SNP associations by age, gender,
family history and MSI status.
Our study has a number of limitations. First, SNP rs4939827
was excluded from our analysis due to genotyping failure;
however, given the perfect linkage disequilibrium (R2 = 1.0 in
HapMap CEU data Release 28.) between rs4939827 and
rs11874392, there is unlikely to have been any loss of information
due to this exclusion. Second, the Bonferroni method to adjust for
multiple comparisons may be so conservative that some potentially
important polymorphisms, such as the variant identified in a
previous GWAS of CRC rs4464148 [3], may be overlooked. On
the other hand, the observed weaker associations of other SMAD7
SNPs (rs4939832, rs1316447, rs4939837, rs7240215) with CRC
risk have not been widely replicated by other studies and therefore
could have been chance findings. Third, we used a case-unaffected
sibling study design that may reduce the power to detect
association between genetic variations and CRC risk because of
overmatching on genotypes between cases and their unaffected
siblings [13]; however, such design does not lead to biases in
estimating genetic relative risks, and is more powerful for detecting
gene-environment interactions and controls for potential con-
founding from population stratification. And lastly, we did not
observe statistically significant associations between these common
Table 5. SNP rs12953713 and rs11874392 by tumor characteristics among population-based families.
Risk associated with T allele of rs12953717 Risk associated with T allele of rs11874392
OR (95% CI)1 PWalds
1 PInteraction




Proximal colon 1.24 (0.96–1.59) 0.10 0.37 0.84 (0.67–1.05) 0.13 0.43
Distal colon 1.49 (1.13–1.95) 0.0041 0.70 (0.54–0.90) 0.0052
Rectum 1.14 (0.90–1.46) 0.28 0.86 (0.67–1.09) 0.22
MSI status
MSS 1.21 (0.98–1.49) 0.073 0.61 0.86 (0.71–1.05) 0.13 0.44
MSI-L 1.52 (0.95–2.44) 0.080 0.69 (0.43–1.10) 0.12
MSI-H 1.41 (0.90–2.20) 0.13 0.67 (0.45–1.00) 0.049
1Adjusted for age and sex. 2P for interaction was estimated from 2 degrees of freedom likelihood-ratio test of the interaction term between the tumor characteristics
and SNP rs12953713.
doi:10.1371/journal.pone.0060464.t005
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SMAD7 SNPs and CRC risk in the clinic-based families, possibly
due to the limited sample size in the clinic-based dataset.
Alternatively, the genetic predisposition in the multiple-case,
clinic-based families may be largely due to other yet-to-be-
identified genetic variations with stronger effects.
In summary, using data from the Colorectal Cancer Family
Registry, we confirmed the association between SMAD7 and CRC
found in GWAS. Further studies are needed to confirm our results
stratified by demographic factors and tumor characteristics and to
elucidate the relevant biological mechanisms. With the growing
epidemiological evidence linking SMAD7 to CRC susceptibility,
studies are needed to investigate potential biological mechanisms
by which SMAD7 contributes to the development of CRC.
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30. Smart NG, Apelqvist ÃA, Gu X, Harmon EB, Topper JN, et al. (2006)
Conditional expression of Smad7 in pancreatic beta cells disrupts TGF-beta
signaling and induces reversible diabetes mellitus. PLoS Biol 4: e39.
31. Gutierrez-Aguilar R, Benmezroua Y, Balkau B, Marre M, Helbecque N, et al.
(2007) Minor contribution of SMAD7 and KLF10 variants to genetic
susceptibility of type 2 diabetes. Diabetes Metab 33: 372–378.
32. Ekman M, Mu Y, Lee SY, Edlund S, Kozakai T, et al. (2012) APC and Smad7
link TGFb type I receptors to the microtubule system to promote cell migration.
Mol Biol Cell 23: 2109–2121.
33. Curtin K, Lin WY, George R, Katory M, Shorto J, et al. (2009) Meta association
of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiol
Biomarkers Prev 18: 616–621.
34. Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, et al. (2009)
Association of common genetic variants in SMAD7 and risk of colon cancer.
Carcinogenesis 30: 982–986.
SMAD7 and Colorectal Cancer Risk
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e60464
